KDM1A and small cell lung carcinoma: Preclinical studies with these inhibitors of LSD1 indicate that the most sensitive cell lines were derived from AML or small cell lung cancer (SCLC) [181], and clinical trials with LSD1 demethylase inhibitors are ongoing for patients with these cancers [52,81].